• OPEN AN ACCOUNT
Indian Indices
Nifty
24,868.60 95.45
(0.39%)
Sensex
81,101.32 314.02
( 0.39%)
Bank Nifty
54,216.10 29.20
( 0.05%)
Nifty IT
35,255.95 945.50
( 2.76%)
Global Indices
Nasdaq
45,544.50 122.63
(0.27%)
Dow Jones
6,517.34 14.84
(0.23%)
Hang Seng
43,525.56 -118.25
(-0.27%)
Nikkei 225
9,221.44 13.23
(0.14%)
Forex
USD-INR
88.19 0.04
(0.05%)
EUR-INR
103.31 0.63
(0.62%)
GBP-INR
119.06 0.66
(0.56%)
JPY-INR
0.60 0.00
(0.61%)

EQUITY - MARKET SCREENER

Enbee Trade & Finance Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
512441
INE993I01029
1.3878501
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
4.27
26.87
EPS(TTM)
Face Value()
Div & Yield %
0.11
1
0
 

Dr Reddy’s Labs UK facility flagged with 7 USFDA observations
Sep 08,2025
According to a regulatory filing, the inspection was conducted from 1 September to 5 September 2025. On conclusion, the USFDA issued a Form-483 with seven observations.

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services, including APIs, generics, branded generics, biosimilars, and OTC.

The company’s consolidated net profit rose 1.8% to Rs 1,418.10 crore on an 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25.

Shares of Dr Reddys Laboratories shed 0.04% to Rs 1,268 on the BSE.